DivestmentAug 7, 2026, 05:24 PM
Cumberland Completes Apotex Divestment; Q2 Net Loss $(4.28)M
AI Summary
Cumberland Pharmaceuticals completed a strategic transaction with Apotex Inc. on July 1, 2026, divesting its FDA-approved products and certain equity interests for $100 million cash. This divestment led to a significant shift in the company's focus towards its proprietary pipeline, particularly ifetroban. For the second quarter of 2026, the company reported a net loss attributable to common shareholders of $(4.28) million, compared to a net loss of $(0.74) million in Q2 2025. Net revenues from continuing operations were $166,458 for the quarter.
Key Highlights
- Completed strategic transaction with Apotex Inc. on July 1, 2026, for $100M cash.
- Net loss attributable to common shareholders was $(4.28) million for Q2 2026.
- Net loss attributable to common shareholders was $(7.57) million for H1 2026.
- Net revenues from continuing operations were $166,458 for Q2 2026.
- Cash and cash equivalents decreased to $3.86 million as of June 30, 2026.
- Repaid $5.2 million revolving line of credit on June 29, 2026.
- Total assets decreased to $62.88 million from $76.82 million (Dec 31, 2025).
- Accumulated deficit increased to $(34.37) million from $(26.80) million.
Price Impact
More from CPIX